CFO4Life Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

CFO4Life Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-7,913	Closed	-$559K	–	231
2025 Q1	$559K	Buy	+7,913	New	+$532K	0.09%	113

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CFO4Life Group's BMRN Position: Q2 2025 in Review

CFO4Life Group sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 7,913 shares — an estimated $559K sold.

CFO4Life Group first reported a position in BMRN in Q1 2025 and held it in 1 quarter. The position peaked at $559K in Q1 2025. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

CFO4Life Group reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
CFO4Life Group sold 7,913 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $559K.
CFO4Life Group first reported a position in BioMarin Pharmaceuticals in Q1 2025 and held it in 1 quarter.
CFO4Life Group's BioMarin Pharmaceuticals position peaked at $559K in Q1 2025.
581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on CFO4Life Group's 13F filing for Q2 2025, filed 8 Aug 2025.